Parabilis Medicines logo

Parabilis Medicines

Challenger

Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline

Best for: AI Peptide Therapeutics
52
AI Score
Grade C
AI Visibility Score (Beta)
HealthcareAI Peptide TherapeuticsWebsiteUpdated November 2026

Brand Intelligence Graph

Integrates with
Capabilities
AI Peptide Therapeutics

Company Overview

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.

Business Model & Competitive Advantage

The company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.

Competitive Landscape 2025–2026

Parabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.

Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

Parabilis Medicines is an established challenger with significant market presence and competitive offerings in Healthcare & Life Sciences.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

52
→ Stable

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Pfizer logo

Pfizer

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan

Moderna logo

Moderna

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép

Amgen logo

Amgen

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Zocdoc logo

Zocdoc

HealthTech
AnalyticsB2bB2cHealthtechMarketplaceMobile FirstPlatformSaas

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati

Doximity logo

Doximity

HealthTech
HealthtechSaasB2bB2cStartupPlatformAi PoweredMobile First

Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic

Compare Parabilis Medicines with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Parabilis Medicines

Claim This Profile

Are you from Parabilis Medicines? Verify your company email to claim this profile and keep its description, products, and FAQs up to date.

Claim Parabilis Medicines Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Parabilis Medicines vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →